Sarcoma and Skin Radiation Oncology

Nedea, Elena; DeLaney, Thomas F.

doi:10.1016/j.hoc.2006.01.017

Cited by 31 publications

(40 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Every year, they account for ~3% of all soft tissue sarcomas, which themselves represent ~1% of all new cancer diagnoses in the United States and Europe (1)(2)(3). Due to their rarity, therapy for fibrosarcomas must be individualised and multimodal.…”

Section: Introductionmentioning

confidence: 99%

“…However, these treatments have shown poor results and are rarely associated with significant improvements in overall survival (10). In disseminated disease, a response rate of 20-30% has been observed with doxorubicin, the most frequently used chemotherapeutic agent in the treatment of soft tissue sarcomas (1,11). Furthermore, the combined use of doxorubicin and ifosfamide demonstrates greater efficacy, with higher response rates compared with those of doxorubicin alone; however, this treatment is associated with severe short-and long-term toxicities, including cardiomyopathy and bone marrow suppression (12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenografts in vivo

et al. 2016

View full text Add to dashboard Cite

Abstract. Fibrosarcomas are rare malignant soft tissue tumours that exhibit a poor response to current therapeutic regimens. Previously, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and taurolidine were observed to induce apoptosis synergistically in HT1080 human fibrosarcoma cells in vitro. Consequently, the present study aimed to assess the safety and efficacy of TRAIL in combination with taurolidine on the local growth of fibrosarcoma xenografts in vivo. HT1080 fibrosarcoma cells were inoculated subcutaneously into both flanks of 49 athymic nude mice in order to establish tumour xenografts. TRAIL and taurolidine were applied intraperitoneally at various single and cumulative treatment doses. After 12 days, the experiment was terminated and surviving animals were euthanised. Tumour progression was determined during and following treatment. To assess the potential toxic effects of the two compounds, the organs (lung, liver, kidney and heart) of all animals were examined histologically. The results revealed that combined treatment with TRAIL and taurolidine significantly inhibited the growth of HT1080 xenografts, whereas untreated animals had steadily increasing tumours. The most effective combination was TRAIL at 2 µg per application (cumulative dose, 16 µg) and taurolidine at 30/15 mg per application (cumulative dose, 180 mg), reducing the mean size of implanted xenografts to 10.9 mm 2 following treatment (vs. 48.9 mm 2 in the control group; P=0.0100). Despite distinct tumour mass reduction, the rate of mortality was significantly increased in animals treated with TRAIL and taurolidine in a taurolidine dose-dependent manner; however, histological examinations of relevant organs revealed no evidence of systemic toxicity (mean survival time, 7.9 days in the treated groups vs. 12 days in the control group; P<0.0010). In summary, whilst the combination of TRAIL and taurolidine synergistically inhibited the growth of fibrosarcoma xenografts in vivo, it was also accompanied by significantly increased mortality rate. Thus, although taurolidine is assumed to be a compound with an acceptable toxicity profile, and therefore increasingly used in clinical trials, the current findings raise concerns with regard to its safety and therapeutic index, and indicate the requirement for further detailed toxicity tests.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenografts in vivo

et al. 2016

View full text Add to dashboard Cite

show abstract

“…At the time of primary diagnosis, about 20% of patients have stage IIB/III disease, as evaluated by American Joint Committee on Cancer (AJCC) [2]. These tumors are high-grade, >5 cm in size, deep to investing fascia and are considered high-risk with a 5-year survival rate of approximately 50% [3]. As reported previously, about 42% of patients with stage IIB/III STS have extensive or locally advanced sarcomas, which makes resection with safe margins and satisfactory functional outcomes very challenging [4].…”

Section: Introductionmentioning

confidence: 99%

Radiographic response to neoadjuvant therapy and its impact on scope of surgery and prognosis in stage IIB/III soft tissue sarcomas

et al. 2013

View full text Add to dashboard Cite

BackgroundNeoadjuvant chemoradiotherapy has been newly included in the NCCN guidelines as a treatment option for stage IIB/III soft tissue sarcomas. Whether radiographic response to neoadjuvant therapy correlates with improved quality of resection and prognosis remains unproven.MethodsData from 120 consecutive patients who were treated with neoadjuvant chemoradiotherapy followed by surgical resection for their locally aggressive limb sarcomas were retrospectively reviewed. Radiographic response was evaluated after neoadjuvant therapy according to Response Evaluation Criteria In Solid Tumors, and data was analyzed for overall survival (OS), local recurrence free survival (LRFS) and metastasis free survival (MFS). Surgical complications and toxicities, as well as functional outcomes, were also analysed.ResultsAfter neoadjuvant chemoradiotherapy, 25 patients (20.8%) had a partial response, 75 patients (62.5%) had stable disease, and 20 patients (16.7%) showed disease progression. Radiographic response to neoadjuvant therapy correlated significantly with improved OS (P = 0.002) and MFS (P < 0.001). Patients with partial response (PR) had a significantly decreased rate of R2 resection as compared with stable disease (SD) and progressive disease (PD) patients (4.0% Vs 21.4%, P < 0.001).ConclusionsRadiographic response to neoadjuvant chemoradiotherapy correlates with improved quality of resection and prognosis in extremity STS patients.

show abstract

“…2 Contemporary treatment of STS requires a multimodality approach utilizing surgery, radiotherapy, and chemotherapy. 3 Although surgery with wide negative margins offers the best chance for cure of localized disease, unacceptably high rates of local recurrence are seen with surgery alone. Consequently, radiation therapy is often used as an adjunct to primary surgical resection to reduce the risk of local recurrence.…”

mentioning

confidence: 99%

A Meta-Analysis of the Association Between Radiation Therapy and Survival for Surgically Resected Soft-Tissue Sarcoma

Lubitz

Rickard

et al. 2018

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

Sarcoma and Skin Radiation Oncology

Cited by 31 publications

References 127 publications

Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenografts in vivo

Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenografts in vivo

Radiographic response to neoadjuvant therapy and its impact on scope of surgery and prognosis in stage IIB/III soft tissue sarcomas

A Meta-Analysis of the Association Between Radiation Therapy and Survival for Surgically Resected Soft-Tissue Sarcoma

Contact Info

Product

Resources

About